Today, the FDA announced its FY 2027 Generic Drug User Fee Amendments (GDUFA) Science and Research Priority Initiatives. The FDA determined the priority initiatives in collaboration with industry and the public, including feedback received during the FY 2026 Generic Drug Science and Research Initiatives Public Workshop.